Research Tree Research Tree Logo

  • Try our Investor Tool
  • Login
  • Sign Up
  • Providers
  • Companies

Research Tree Logo

  • Features
  • Pricing
  • RNS/News
  • Contact
  • Try our Investor Tool
  • Login
  • Sign Up
  • Providers
  • Companies
  • Features
  • Pricing
  • RNS/News
  • Short Interest Tracker
  • Blogs
    • Academy
    • Insights
    • News
    • Research Tree
    • The Naked Fund Manager
  • Ideas & Picks
    • Ideas Hub
    • Stock Pick League
    • Themes & Screens Hub
  • Explore Content
    • Regions
      UK Rest of EMEA N America APAC LatAm
    • Sectors
      Automobile Industry Banks Building & Construction Chemicals Discretionary Personal Goods Discretionary Retail Energy Financial Services Food & Drink Food Production Health Household Goods & DIY Industrial Equipment, Goods & Services Insurance & Reinsurance Leisure, Tourism & Travel Media Other Real Estate Resources Staple Retail Technology Telecoms Trusts, ETFs & Funds Utilities
    • Small / Large Cap
      UK100 UK250 UK Smallcap UK Other Main Markets Other
    • Private/EIS
      EIS Single Company EIS/SEIS Funds IHT Products SEIS Single Company VCT Funds
  • Providers
    • Free/Commissioned
      Align Research BRR Media Capital Access Research Edison Equity Development Fidante Partners Five Minute Pitch TV goetzpartners securities Limited Hardman & Co Independent Investment Research Kepler | Trust Intelligence piworld.co.uk Proactive Investors Progressive Equity Research QuotedData Radnor Capital Partners Research Tree Trinity Delta
    • High Net Worth Offering
      Allenby Capital AlphaValue Arden Partners Cenkos Securities finnCap GMP FirstEnergy Hybridan Liberum Louis Capital Marten & Co Medley Global Advisors N+1 Singer Northland Capital Partners SP Angel Stockdale Securities VSA Capital WHIreland Whitman Howard Zeus Capital
    • Institutional Offering
      Align Research Allenby Capital AlphaValue Arden Partners BRR Media Capital Access Research Cenkos Securities Edison Equity Development Fidante Partners finnCap Five Minute Pitch TV GMP FirstEnergy goetzpartners securities Limited Hardman & Co Hybridan Independent Investment Research Kepler | Absolute Hedge Kepler | Trust Intelligence Liberum N+1 Singer Northland Capital Partners piworld.co.uk Proactive Investors Progressive Equity Research QuotedData Radnor Capital Partners Research Tree SP Angel Stockdale Securities Trinity Delta VSA Capital WHIreland Whitman Howard Zeus Capital
    • Video/Audio Interviews
      BRR Media Edison Equity Development Five Minute Pitch TV piworld.co.uk Proactive Investors Research Tree
  • Contact
Companies >
Belgium >
Biotechnology >
Celyad >
Research >
Revision of clinical strategy after responses seen

  • 30 Oct 2017

- Revision of clinical strategy after responses seen


Celyad | CYAD | 0 0 (-0.8%) | Mkt Cap: 331.6m


  • Edison
    • Dr John Savin

    • 7 pages

Biotechnology image



 
Biotechnology image



Celyad has reported a complete morphological leukemia-free status (MFLS) response in acute myeloid leukemia (AML) in the NKR CAR T-cell THINK study. Spontaneous remission in refractory/relapsed AML is extremely rare, so this is a significant result. Importantly, the response was achieved with no toxic preconditioning. CYAD-01 has shown limited toxicities to date. The clinical strategy has been updated to focus on AML and colorectal cancer. Additionally, with the approvals of Yescarta (Gilead) at a price of $373k and Kymirah (Novartis) at $475k, we have increased our expected price for NRK CAR T-cell therapy to $200k, formerly $150k. The revised strategy and price assumption change moves the indicative value to $122 per ADR, formerly $61 per ADR.


Celyad found one AML patient given 3x108 NKR CAR T-cells had a complete MLFS response. In effect, it was a near CRi; that is, a complete response with high but not normal blood cell levels. Treatment with NKR CAR T-cells has enabled him to move to stem cell transplant. Median survival of relapsed and refractory AML patients is typically less than four months (source Celyad, see AML treatment).


With a near complete response in AML and two stable disease cases at low dose in colorectal cancer, Celyad has decided to focus its development efforts on these two indications. The current THINK study in AML, MM and five solid cancers, including colorectal, will continue to find the optimal dose but with preferential recruitment of AML and colorectal patients. Celyad also intends to evaluate combination therapies. As the first such study, the SHRINK trial of CYAD-01 is ready to start recruitment in metastatic CRC in combination with FOLFOX chemotherapy. 


Our previous approach to valuing the Celyad NKR CAR T-cells portfolio was to treat AML and MM as defined indications with a probability of 20% and to take a weighted average of the five solid tumor indications. We have now focused the valuation on AML at 25% probability and colorectal at 20% (adjusted from 10% in August). The C-Cure a cardiac indication is still seeking a partner so is now given a nominal value of $12m, formerly $191m. Rebasing the valuation to January 2018 gives a new indicative value of €$1,236m, formerly $616m (indicating $122 per ADR (formerly $61)). Management states that Celyad has cash to fund it through the first half of 2019. Additional cash might enable a broader and faster development of the clinical program given its promising current outlook. 


Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

More Content

More Content

Celyad - Blasts get blasted but dose needs definition

Companies: Celyad

Edison

Waiting for the Roman results

Companies: Celyad

Edison

Celyad - Allogeneic trial first dose given

Companies: Celyad

Edison

Joining the US CAR club

Companies: Celyad

Edison

Celyad - Highly encouraging data on dose responses

Companies: Celyad

Edison

Useful Links

  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub

Account

  • Login
  • Free Trial - Join Now
  • Contact
Follow us on Linkedin Follow us on Twitter

Share:

Heap | Mobile and Web Analytics

Copyright © 2019 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Tools licensed and contents implemented and optimized by Digital Look Ltd.

DigitalLook |Web Financial Group

©1999-2013 – Digital Look Ltd. A Web Financial Group Company All rights reserved. Legal notice.

Top
  • Home
  • Features
  • Pricing
  • RNS/News
  • Short Interest Tracker
  • Blogs
    • Academy
    • Insights
    • News
    • Research Tree
    • The Naked Fund Manager
  • Ideas & Picks
    • Ideas Hub
    • Stock Pick League
    • Themes & Screens Hub
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Leisure, Tourism & Travel
      • Media
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Align Research
      • BRR Media
      • Capital Access Research
      • Edison
      • Equity Development
      • Fidante Partners
      • Five Minute Pitch TV
      • goetzpartners securities Limited
      • Hardman & Co
      • Independent Investment Research
      • Kepler | Trust Intelligence
      • piworld.co.uk
      • Proactive Investors
      • Progressive Equity Research
      • QuotedData
      • Radnor Capital Partners
      • Research Tree
      • Trinity Delta
    • High Net Worth Offering
      • Allenby Capital
      • AlphaValue
      • Arden Partners
      • Cenkos Securities
      • finnCap
      • GMP FirstEnergy
      • Hybridan
      • Liberum
      • Louis Capital
      • Marten & Co
      • Medley Global Advisors
      • N+1 Singer
      • Northland Capital Partners
      • SP Angel
      • Stockdale Securities
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Zeus Capital
    • Institutional Offering
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Arden Partners
      • BRR Media
      • Capital Access Research
      • Cenkos Securities
      • Edison
      • Equity Development
      • Fidante Partners
      • finnCap
      • Five Minute Pitch TV
      • GMP FirstEnergy
      • goetzpartners securities Limited
      • Hardman & Co
      • Hybridan
      • Independent Investment Research
      • Kepler | Absolute Hedge
      • Kepler | Trust Intelligence
      • Liberum
      • N+1 Singer
      • Northland Capital Partners
      • piworld.co.uk
      • Proactive Investors
      • Progressive Equity Research
      • QuotedData
      • Radnor Capital Partners
      • Research Tree
      • SP Angel
      • Stockdale Securities
      • Trinity Delta
      • VSA Capital
      • WHIreland
      • Whitman Howard
      • Zeus Capital
    • Video/Audio Interviews
      • BRR Media
      • Edison
      • Equity Development
      • Five Minute Pitch TV
      • piworld.co.uk
      • Proactive Investors
      • Research Tree
  • Contact
  • Sign Up
  • Sign In